动脉输注吉西他滨治疗103例晚期肿瘤的疗效观察  

Study of curative effect of infusion gemcitabine via artery for 103 cases with advanced cancer

作　　者：徐卫东[1] 陈世晞[1] 方婕[1] 吴建达[1] 吴美琦[1] 尹国文[1] 席玮[1] 陈骏[1] 

机构地区：[1]江苏省肿瘤医院介入科,江苏南京210009

出　　处：《河北医学》2003年第10期869-872,共4页Hebei Medicine

摘　　要：目的 :观察经动脉输注吉西他滨治疗晚期肿瘤的疗效。方法 :1 0 3例经病理证实的晚期肿瘤患者 ,在病程的某个阶段 ,经动脉途经输注以吉西他滨为主的化疗药物及免疫增强剂IL - 2。结果 :6 8例胰腺癌患者中有 2 9.4 %获疼痛程度、止痛剂用药显著而持久的改善。受益反应持续时间为1 9.2周 ,中位生存期 7.1 3个月 ;6个月、9个月、1 2个月的生存率分别为 4 5 .6 %、2 3.5 %、1 7.6 % ,1 1例胆囊癌患者中有 2 7.3%获疼痛程度、止痛剂用量的显著而持久的改善 ,临床受益反应持续时间为 1 8.8周 ,中位生存期 7.4 5个月 ;6个月、9个月、1 2个月的生存率分别为 5 4.5 %、2 7.3%、1 8.2 %。 8例非小细胞肺癌有效率达 6 2 .5 % ,1年生存率 37.5 % ;6例肠癌有效率达 83.3% ,1年、2年生存率分别为 6 6 .7%、33.3% ;7例肝癌有效率 85 .7% ,1年、2年生存率分别为 71 .4 %、4 2 .9%。结论 :经动脉输注吉西他滨能明显改善晚期肿瘤的生活质量 。Objective: To observe the efficacy of infusion gemcitabine via artery for advanced cancer. Methods:103 cases advanced cancer proved by pathology,received the chemotherapy combining gemciabine plus IL-2 infused into artery , in some stage of course. Results: In 68 pancreatic cancer,the obvious improvement in pain was 29.4%,the duration of clinical benefit responses was 19.2 weeks, the survival rate was 45.6%,23.5%,17.6%, with median survival of 7.13,6,9,12 months. In 11 gallbladder cancer, the obvious improvement in pain was 27.2%, the duration of CBR was 18.8 weeks, the survival rates was 54.5%,27.3%,18.2% with median survival of 7.45,6 ,9,12months. The response rate was 62.5% in 8 non-small cell lung cancer, 1 year survival rate was 37.5%.In 6 eolorectal cancer and 7 liver cancer,the response rates was 83.3% and 85.7% . 1,2 years survival rates was 66.7% , 33.3% and 71.4% , 42.9%. Conclusions: Infusion gemcitabine via artery can not only prolong survival rate but also improve life of quality.

关 键 词：晚期肿瘤 吉西他滨 输注 动脉内 

分 类 号：R730.5[医药卫生—肿瘤]